BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, December 31, 2025
Home » Topics » Immune, BioWorld Science

Immune, BioWorld Science
Immune, BioWorld Science RSS Feed RSS

Transmission electron micrograph of HIV-1 virus particles
HIV/AIDS

IAS 2025: All eyes still on the HIV reservoir

July 16, 2025
By Mar de Miguel
No Comments
While people living with HIV can lead virtually normal lives thanks to antiretroviral therapy (ART), HIV persists in a latent state within cellular reservoirs that scientists do not know how to eliminate. “Transcription is a critical step in the viral life cycle. … But there are currently no drugs suppressing HIV transcription, and that may be one of the reasons why current antiretroviral therapy is not curative,” Melanie Ott told the audience at the 13th IAS Conference on HIV Science this week in Kigali, Rwanda.
Read More
Immune

IRF5 inhibitors show efficacy across autoimmune models

July 9, 2025
No Comments
Interferon regulatory factor 5 (IRF5) is a transcription factor activated downstream of Toll-like receptors (TLRs) 7, 8 and 9, and is predominantly expressed in dendritic cells, B cells, monocytes and macrophages. Once considered an undruggable target, IRF5 is now recognized as a key regulator of innate immunity, driving the production of type I interferons, pro-inflammatory cytokines and autoantibodies.
Read More
Illustration of monoclonal antibody hovering between doctor's hands
Immune

Oxion’s anti-OX40L antibody shows potential for disease-modifying effects

July 7, 2025
No Comments
The OX40/OX40L costimulatory pathway is crucial for effective T-cell activation and is inducibly expressed in response to immunological stimulation. Targeting OX40L has demonstrated safety and efficacy in preclinical studies using nonhuman primate models of kidney and heart transplantation.
Read More
3D rendering of a molecular glue mediating the interaction between two proteins
Drug design, drug

With surface mimicry, molecular glues shed hairpin need

July 7, 2025
By Anette Breindl
No Comments
Degradation is a therapeutic strategy that could offer possibilities to get at currently undruggable target proteins. In targeted degradation, compounds induce interactions between a target protein and a protein that can tag the target for degradation. In principle, there are several pathways that could be used for such tagging; the most attention has gone to ubiquitin ligases, in particular cereblon, a protein that is part of a ubiquitin ligase complex and the target of several approved drugs.
Read More
Molecule illustration
Immune

Unnatural Products joins Argenx in a $1.5B macrocyclic deal

July 2, 2025
By Lee Landenberger
No Comments
Unnatural Products Inc. notched another collaboration by signing on with Argenx SE in a multitarget research collaboration. Unnatural Products, which is getting up-front, near-term payments and R&D funding, could end up with about $1.5 billion in milestones and options payments plus tiered royalties on net sales.
Read More
Cell research illustration
Inflammatory

Immune checkpoint enhancer ALTB-268 decreases inflammation

July 2, 2025
No Comments
Agonists of immune checkpoint modulators for treating autoimmune and inflammatory disorders have shown high potential in immunotherapy. P-selectin glycoprotein ligand 1 (PSGL-1) is known to exert immune checkpoint regulator functions in T cells aside from its classic role as an adhesion molecule involved in leukocyte trafficking.
Read More
Illustration of anatomy of a human embryo at 7 weeks
Cardiovascular

CRVBC: Cardiac diseases can start in utero after immune migration

July 2, 2025
By Mar de Miguel
No Comments
A healthy life for a healthy heart is a popular saying. However, even when following good habits, heart health can be already compromised from the very earliest stages of development. Maternal cells reach the embryo through the placenta contributing to its normal formation. So, just as the mother helps form a functional heart, she can also induce a condition that may not appear until adulthood.
Read More
Neurology/psychiatric

MRT-6160 VAV1 molecular glue blocks EAE in preclinical models

July 1, 2025
No Comments
VAV1 is a guanine nucleotide exchange factor essential for T- and B-cell receptor signaling, with expression largely restricted to immune cells. Loss of VAV1, via CRISPR or genetic deletion, impairs effector functions in both T and B cells.
Read More
Inflammatory

Sanofi to advance KT-485 into clinic under IRAK-4 partnership with Kymera

June 26, 2025
No Comments
Sanofi SA has selected KT-485 (SAR-447971) to advance into clinical studies under its IRAK-4 partnership with Kymera Therapeutics Inc.
Read More
Microscopic image of Group A streptococcus bacteria.
Immune

Evaxion unveils new vaccine program to prevent group A Streptococcus infections

June 26, 2025
No Comments
Evaxion A/S has added a new vaccine program, named EVX-B4, to its pipeline for prevention of group A Streptococcus (GAS) infections. Invasive GAS infections can cause diseases such as sepsis, toxic shock, rheumatic heart disease and necrotizing fasciitis.
Read More
Previous 1 2 … 10 11 12 13 14 15 16 17 18 … 564 565 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 31, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 31, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Businessman, businesswoman handshake

    Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact

    BioWorld
    Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
  • Asia focused map inside light bulb

    Big pharma taps fast Asia innovation in search of next Keytruda

    BioWorld
    Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing